Cellectis develops cell therapies for cancer and genetic diseases using gene editing, and licenses its technology to drug developers. CLLS reports earnings on Fri, Nov 13, 2026. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 1 hold, 1 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 16 | Barclays | Downgrade | Sell | |
| Sep 15 | Wells Fargo | Maintained | Hold | |
| Sep 15 | Baird | Maintained | Buy | |
| May 28 | Barclays | Initiated | Buy |
Seasonality
How CLLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in CLLS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLLS is in one of them and how their past CLLS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CLLS in an article yet. Here's the latest on the wider market.
About Cellectis S.A.
Cellectis is a biotechnology company based in Paris, France, that develops cell and gene therapies using gene editing. Its main focus is cancer treatments made from CAR T cells taken from healthy donors, which can be produced in batches and shipped as ready to use products rather than made for each patient. The company also develops gene therapies for genetic diseases and licenses its technology to drug developers such as AstraZeneca, Allogene, Servier and Iovance.
- Headquarters
- Paris, Lle-De-France
- Founded
- 1999
- Website
- cellectis.com ↗